CytomX Therapeutics, Inc. - Product Pipeline Review - 2016

  • ID: 3775423
  • Company Profile
  • 42 pages
  • Global Markets Direct
  • CytomX Therapeutics Inc
1 of 4
CytomX Therapeutics, Inc. - Product Pipeline Review - 2016

Summary

‘CytomX Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the CytomX Therapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by CytomX Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of CytomX Therapeutics, Inc.
- The report provides overview of CytomX Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses CytomX Therapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features CytomX Therapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate CytomX Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for CytomX Therapeutics, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding CytomX Therapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

CytomX Therapeutics, Inc. Snapshot

CytomX Therapeutics, Inc. Overview

Key Information

Key Facts

CytomX Therapeutics, Inc. - Research and Development Overview

Key Therapeutic Areas

CytomX Therapeutics, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

CytomX Therapeutics, Inc. - Pipeline Products Glance

CytomX Therapeutics, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

CytomX Therapeutics, Inc. - Drug Profiles

CTX-023

Product Description

Mechanism of Action

R&D Progress

CTX-033

Product Description

Mechanism of Action

R&D Progress

CTX-1003

Product Description

Mechanism of Action

R&D Progress

CX-072

Product Description

Mechanism of Action

R&D Progress

CX-2009

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugate to Target CD-71 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugate to Target ITGA-3 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugated to Target CD3 and EGFR for Solid Tumor

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugates 1 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugates 2 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Antagonize CTLA4 for Oncology

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies 1 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies 2 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugates 3 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugates for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Antagonize Interleukin-6 Receptor for Inflammation

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Antagonize PD-1 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit Glycoprotein-130 for Inflammation

Product Description

Mechanism of Action

R&D Progress

CytomX Therapeutics, Inc. - Pipeline Analysis

CytomX Therapeutics, Inc. - Pipeline Products by Target

CytomX Therapeutics, Inc. - Pipeline Products by Molecule Type

CytomX Therapeutics, Inc. - Pipeline Products by Mechanism of Action

CytomX Therapeutics, Inc. - Recent Pipeline Updates

CytomX Therapeutics, Inc. - Dormant Projects

CytomX Therapeutics, Inc. - Locations And Subsidiaries

Head Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

CytomX Therapeutics, Inc., Key Information

CytomX Therapeutics, Inc., Key Facts

CytomX Therapeutics, Inc. - Pipeline by Indication, 2016

CytomX Therapeutics, Inc. - Pipeline by Stage of Development, 2016

CytomX Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016

CytomX Therapeutics, Inc. - Preclinical, 2016

CytomX Therapeutics, Inc. - Discovery, 2016

CytomX Therapeutics, Inc. - Pipeline by Target, 2016

CytomX Therapeutics, Inc. - Pipeline by Molecule Type, 2016

CytomX Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016

CytomX Therapeutics, Inc. - Recent Pipeline Updates, 2016

CytomX Therapeutics, Inc. - Dormant Developmental Projects,2016

List of Figures

CytomX Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016

CytomX Therapeutics, Inc. - Pipeline by Stage of Development, 2016

CytomX Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016

CytomX Therapeutics, Inc. - Pipeline by Top 10 Target, 2016

CytomX Therapeutics, Inc. - Pipeline by Molecule Type, 2016

CytomX Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll